Cargando…

Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yifang, Ricardo, Sharon D., Samuel, Chrishan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181689/ https://www.ncbi.nlm.nih.gov/pubmed/35682717 http://dx.doi.org/10.3390/ijms23116035

Ejemplares similares

Anti-fibrotic Potential of AT(2) Receptor Agonists
por: Wang, Yan, et al.
Publicado: (2017)

Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1
por: Pinar, Anita A., et al.
Publicado: (2020)

Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms
por: Hazrati, Ali, et al.
Publicado: (2022)

The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate
por: Wang, Chao, et al.
Publicado: (2016)

A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat
por: Gilbert, Richard E., et al.
Publicado: (2012)

Microvascular Targets for Anti-Fibrotic Therapeutics
por: Pu, Kai-Ming T., et al.
Publicado: (2013)

A Novel Approach to Enhance the Regenerative Potential of Circulating Endothelial Progenitor Cells in Patients with End-Stage Kidney Disease
por: Badawi, Amrilmaen, et al.
Publicado: (2022)

P1002: ANTI-FIBROTIC ACTIVITY OF BMP2 IN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS OF MYELOPROLIFERATIVE NEOPLASMS
por: Subotički, T., et al.
Publicado: (2022)

Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents
por: Börger, Verena, et al.
Publicado: (2017)

Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use
por: Jimenez-Puerta, Gonzalo José, et al.
Publicado: (2020)

Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics
por: Dolivo, David, et al.
Publicado: (2021)

The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery
por: Hochheuser, Caroline, et al.
Publicado: (2021)

The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice
por: Al-Rubaie, Ali, et al.
Publicado: (2018)

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms
por: Schneider, Rebekka K, et al.
Publicado: (2014)

Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors
por: Tapia Cáceres, Felipe, et al.
Publicado: (2022)

Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
por: Fintha, Attila, et al.
Publicado: (2019)

Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell
por: Iwata, Yasunori, et al.
Publicado: (2021)

Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases
por: Miao, Changxiu, et al.
Publicado: (2022)

The Therapeutic Potential of Zinc-Alpha2-Glycoprotein (AZGP1) in Fibrotic Kidney Disease
por: Sörensen-Zender, Inga, et al.
Publicado: (2022)

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step
por: Weiskirchen, Ralf
Publicado: (2016)

Antisense Oligonucleotides against Let-7 Enhance the Therapeutic Potential of Mesenchymal Stromal Cells
por: Lee, Dae-Won, et al.
Publicado: (2023)

Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases
por: Lopes-Pacheco, Miquéias, et al.
Publicado: (2023)

Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases
por: Chen, Yingqing, et al.
Publicado: (2021)

Anti‐Inflammatory and Anti‐Fibrotic Effects of Human Amniotic Membrane Mesenchymal Stem Cells and Their Potential in Corneal Repair
por: Navas, Alejandro, et al.
Publicado: (2018)

Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target
por: Marangoni, Roberta G., et al.
Publicado: (2017)

Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells
por: Merino, Ana, et al.
Publicado: (2021)

Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis
por: Rozier, Pauline, et al.
Publicado: (2021)

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
por: Di Gregorio, Jacopo, et al.
Publicado: (2020)

Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents
por: Sanz-Nogués, Clara, et al.
Publicado: (2021)

The Novel AT2 Receptor Agonist β-Pro7-AngIII Exerts Cardiac and Renal Anti-Fibrotic and Anti-Inflammatory Effects in High Salt-Fed Mice
por: Wang, Yan, et al.
Publicado: (2022)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
por: Mohamad Anuar, Nur Najmi, et al.
Publicado: (2020)

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells
por: Hicks, Daniel F., et al.
Publicado: (2017)

Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action
por: Karatzas, Evangelos, et al.
Publicado: (2021)

Mesenchymal stromal cells as a potential therapeutic for neurological disorders()
por: Mukai, Takeo, et al.
Publicado: (2018)

Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells
por: Cuesta-Gomez, Nerea, et al.
Publicado: (2021)

Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan
por: Chen, Dan-Qian, et al.
Publicado: (2019)

Anti-Fibrotic Effect of Synthetic Noncoding Decoy ODNs for TFEB in an Animal Model of Chronic Kidney Disease
por: Lee, Sun-Jae, et al.
Publicado: (2022)

Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer
por: Ramakrishnan, Puvanesswaray, et al.
Publicado: (2020)

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease
por: Rota, Cinzia, et al.
Publicado: (2018)

Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury
por: Ullah, Mujib, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fv4p2qs8s3kjc16njv3rdp2hha